Zoetis Inc. $ZTS Shares Bought by Soltis Investment Advisors LLC

Posted by Brian Himes on Oct 30th, 2026

Soltis Investment Advisors LLC raised its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 58.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 129,952 shares of the company’s stock after buying an additional 48,180 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Zoetis were worth $9,075,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. BlackRock Inc. raised its holdings in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. State Street Corp boosted its position in shares of Zoetis by 1.8% during the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after acquiring an additional 343,322 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Zoetis by 7.3% during the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after acquiring an additional 327,313 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Zoetis by 5.8% in the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares during the period. Finally, Swedbank AB grew its holdings in shares of Zoetis by 9.9% in the first quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock valued at $355,126,000 after purchasing an additional 269,610 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS opened at $78.81 on Friday. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $145.04. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.56 billion, a P/E ratio of 11.82, a P/E/G ratio of 1.15 and a beta of 0.74. The stock’s fifty day moving average is $74.95 and its two-hundred day moving average is $93.86.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts expect that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s payout ratio is 34.93%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZTS shares. Citigroup cut their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a report on Tuesday, August 25th. Stifel Nicolaus decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. UBS Group increased their price target on shares of Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, William Blair downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $98.20.

View Our Latest Report on Zoetis

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: The FDA approved Convenia RTU, a single-dose injectable antibiotic for dogs. The product expands Zoetis’ companion-animal portfolio and could provide a new source of prescription revenue. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
Positive Sentiment: Analysts and Zacks’ earnings indicators point to the possibility of a third-quarter earnings beat, which may be improving sentiment ahead of the report. Zoetis expected to beat earnings estimates
Neutral Sentiment: Zacks Research upgraded Zoetis from “strong sell” to “hold.” The move reduces negative pressure but stops short of signaling a bullish outlook. Zacks Research stock recommendations
Neutral Sentiment: A valuation-compression thesis argues that Zoetis may be inexpensive relative to animal-health peers IDEXX Laboratories and Elanco, while livestock and international sales have helped offset weakness in U.S. pet care. Zoetis versus IDEXX and Elanco valuation analysis
Negative Sentiment: Investors remain concerned that weaker U.S. pet-care demand and lower company guidance could limit a broader recovery, making the upcoming earnings report and outlook important catalysts.

Zoetis Company Profile

(Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.